Izlaganje sa skupa

DO CANNABIS AND CANNABINOIDS HAVE A PSYCHOPHARMACOTHERAPEUTIC EFFECT?

Izet Pajević ; Department of Psychiatry University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina ; Faculty of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Mevludin Hasanović ; Department of Psychiatry University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina ; Faculty of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Nera Žigić ; Department of Psychiatry University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina ; Faculty of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Ahmed Pajević ; Department of Psychiatry University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina : Faculty of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Leila Avdić ; Department of Neurology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina

Sažetak

Backgrounds: Written historical evidence reveals that Cannabis sativa has been used medically, recreationally and spiritually
for more than five centuries in many cultures. It is considered the most-used plant-based psychoactive substance with millions of
different usages across the world. To review what the studies, conducted over the past two decades, indicate about effects of the
cannabis on physical and mental health as well as the impact on social functioning.
Methods: We selected literature review using PubMed resources, to summarize the findings of the existing publications on
cannabis and cannabinoids and their possible psychopharmacological therapeutic effects only.
Results: Research supports cannabis' clear acute effect on neurocognition, while non-acute effects for prolonged use of
marijuana are unclear and still insufficiently explored.Due to cannabidiol's (CBD) safety and tolerability, the absence of
psychoactive or cognitive effects, the existence of clinical trials with positive results and its broad pharmacological spectrum, CBD is
a cannabinoid whose initial results will likely lead to implementation into clinical practice. The fact that the results of previous
studies establish the claim of CBD as an antipsychotic and anxiolytic, makes the above developments even more likely. However,
long-term, double-blind, placebo studies with samples of patients with different psychotic and anxiety disorders are still necessary.
Likewise, due to CBD's biphasic effects, determining an adequate therapeutic dose remains a challenge to conclude, the cannabinoid
system represents a promising target for new therapeutic interventions in psychiatry.
Conclusion: Further controlled studies are essential to determine the precise mechanisms of action of cannabinoids on various
neuropsychiatric disorders as well as the safety of their use are needed. Never just the use of 'smoking cannabis in an unlicenced
way'. The use of simple 'smoked cannabis' remains dangerous because of the effects on inducing psychosis which the article itself
refers to, and needs to remain illegal.

Ključne riječi

cannabis; cannabinoids; psychopharmacological therapeutic effects

Hrčak ID:

275417

URI

https://hrcak.srce.hr/275417

Datum izdavanja:

19.10.2021.

Posjeta: 253 *